Compensation to patient [Regulatives / Guidelines]

posted by drgunasakaran1  – 2025-01-23 01:52 (24 d 08:29 ago) – Posting: # 24345
Views: 430

❝ For Bioequivalence study conducted on patients, do we need to provide financial compensation to patients for the participation i.e. Housing or blood loss for Pharmacokinetic evaluation? any guideline from DCGI/ICMR or any regulatory body?

Dear Pharma_88,
It is essential to provide appropriate compensation to patients who participate in bioequivalence studies. The amount of compensation is typically subject to approval by the Ethics Committee, which assesses the proposed compensation to ensure that it is justified and ethical.

Dr Gunasakaran Sambandan MD
Disclaimer: The replies/posts are my personal opinions, and they do not represent my company's views on the same. LinkedIn

Complete thread:

UA Flag
Activity
 Admin contact
23,381 posts in 4,914 threads, 1,662 registered users;
34 visitors (0 registered, 34 guests [including 10 identified bots]).
Forum time: 10:21 CET (Europe/Vienna)

Science is built up with facts, as a house is with stones.
But a collection of facts is no more a science
than a heap of stones is a house.    Henri Poincaré

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5